London (PRWEB) October 10, 2013
The US personalized cancer Genome Sequencing market is primarily classified into Targeted Genome Sequencing and Whole-Genome Sequencing. Our report entitled “US Personalized Cancer Genome Sequencing Market” takes into account the Whole-Genome Sequencing services, which is one of the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment.
In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome Sequencing market, our report has effectively studied the current and future status of cancer in the US as well as its States. In view of the fact that cancer affects some specific age groups in a significant manner, we have also investigated the age-wise statistics of the disease. To get proper insight into the market, an in-depth analysis into the high-income group population is provided so that players can have a clear picture about their potential customer base and the market to be tapped.
The WGS industry has evolved in US in the recent times, and the level and seriousness of implementation has seen drastic changes. An in-depth study of the regulatory environment governing the US personalized cancer Whole-Genome Sequencing market has also been provided. It has been found that regulations related to personalized cancer sequencing are primarily governed with the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them.
The report analyzes the competitive landscape in the market by properly analyzing the business, services and activities of the companies. It also provides the competitive benchmarking, taking into account the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for the clients who want to get an in-depth understanding of the market.
1. Analyst View
2. Research Methodology
3. Cancer Statistics by Demographics
3.1 Prevalence, Incidences, and Mortality (2009-2017)
3.2 Leading States by Incidence
3.3 Leading Cancers by Incidence
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Age-Group
4. US Personalized Cancer WGS Potential Market
5. US Personalized Cancer WGS: Current and Future Market Analysis
6. Regulatory Insights
6.1 Clinical Laboratory Improvement Amendments (CLIA) Accreditation
6.2 CAP Accreditation
7. Market Constraints
8. Competitive Assessment
8.1 Illumina
8.1.1 Business Overview
8.1.2 Strengths and Weaknesses
8.2 Complete Genomics
8.2.1 Business Overview
8.2.2 Strengths and Weaknesses
8.3 Beckman Coulter Genomics
8.3.1 Business Overview
8.3.2 Strengths and Weaknesses
8.4 Expression Analysis
8.4.1 Business Overview
8.4.2 Strengths and Weaknesses
8.5 EdgeBio
8.5.1 Business Overview
8.5.2 Strengths and Weaknesses
8.6 Foundation Medicine
8.6.1 Business Overview
8.6.2 Strengths and Weaknesses
8.7 SeqWright
8.7.1 Business Overview
8.7.2 Strengths and Weaknesses
8.8 Ambry Genetics
8.8.1 Business Overview
8.8.2 Strengths and Weaknesses
8.9 BGI Americas Corporation
8.9.1 Business Overview
8.9.2 Strengths and Weaknesses
8.10 Cofactor Genomics
8.10.1 Business Overview
8.10.2 Strengths and Weaknesses
List of Figures:
Figure 3-1: Cancer Prevalence (Million), 2009-2017
Figure 3-2: Cancer Incidences (‘000), 2009-2017
Figure 3-3: Cancer Mortality (‘000), 2009-2017
Figure 3-4: Incidences by Type of Cancer (%), 2013
Figure 3-5: Top Five States with Highest Cancer Incidences (‘000), 2013
Figure 3-6: Cancer Incidences by Age Group (%)
Figure 4-1: Potential Customers for Personalized Cancer WGS Market (‘000), 2012-2017
Figure 4-2: Potential Customers for Personalized Cancer WGS Market by Age-Group (%), 2013
Figure 4-3: Potential Market for Personalized Cancer WGS (Billion US$), 2012-2017
Figure 5-1: Tapped and Untapped Personalized Cancer WGS Market (%), 2013
Figure 5-2: Personalized Cancer WGS Market (Million US$), 2012-2017
List of Tables:
Table 3-1: Top 10 Cancer Incidences in Males (2013)
Table 3-2: Top 10 Cancer Incidences in Females (2013)
Table 4-1: Key Demographics and Potential Customers for Personalized Cancer WGS Market (2012)
Read the full report:
US Personalized Cancer Genome Sequencing Market
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com